BI 456906

Development code for the investigational drug survodutide, a 29-amino-acid peptide based on the glucagon molecule with positions modified towards GLP-1 and exendin-4. It is a dual co-agonist of the GLP-1 and glucagon receptors developed by Boehringer Ingelheim and Zealand Pharma. It is neither authorised nor marketed in Spain.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.